Arcutis Biotherapeutics presented new caregiver-reported data from the INTEGUMENT-INFANT trial showing that ZORYVE (roflumilast) cream 0.05% improves itch, symptoms, and quality of life in infants aged 3 to 24 months with mild to moderate atopic dermatitis. The cream was well tolerated with no serious adverse events reported. These findings support Arcutis's supplemental FDA application to expand ZORYVE's use to younger infants, addressing a significant unmet need for safe, steroid-free treatment options in this vulnerable population.
Arcutis's new caregiver-reported outcomes data on ZORYVE cream for infant atopic dermatitis is presented alongside a snapshot of the health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 20:42 WIB: out of 150 priced US health-sector stocks, 107 rose and 39 fell. Notable movers include TNGX at USD 24.00 with a 1-day change of -3.42% and a typical hold time of 4 days, AHCO at USD 7.68 down 2.41% with 100% sell order activity and a 21-day hold time, and ABCL at USD 11.87 up 2.15% with 79% buy order activity and a 42-day hold time.
The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...
REalloys Inc. reported a net loss of $30.5 million in Q3 2026 but made significant progress by signing a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot, Utah. The company is advancing its met...
Modern Mining Technology Corp. began trading on the NYSE American after raising nearly $40 million in an IPO. The company recovers valuable metals like gold, silver, and copper from electronic waste using a proprietary process, avoiding traditional m...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
